Hemostemix Inc. (HEM.V)

CAD 0.1

(0.0%)

Total Debt Summary of Hemostemix Inc.

  • Hemostemix Inc.'s latest annual total debt in 2023 was 4.32 Million CAD , up 4.74% from previous year.
  • Hemostemix Inc.'s latest quarterly total debt in 2024 Q1 was 4.46 Million CAD , up 3.36% from previous quarter.
  • Hemostemix Inc. reported annual total debt of 4.12 Million CAD in 2022, up 178.43% from previous year.
  • Hemostemix Inc. reported annual total debt of 1.48 Million CAD in 2021, up 746.75% from previous year.
  • Hemostemix Inc. reported quarterly total debt of 4.46 Million CAD for 2024 Q1, up 3.36% from previous quarter.
  • Hemostemix Inc. reported quarterly total debt of 4.32 Million CAD for 2023 FY, up 4.74% from previous quarter.

Annual Total Debt Chart of Hemostemix Inc. (2023 - 2013)

Historical Annual Total Debt of Hemostemix Inc. (2023 - 2013)

Year Total Debt Total Debt Growth
2023 4.32 Million CAD 4.74%
2022 4.12 Million CAD 178.43%
2021 1.48 Million CAD 746.75%
2020 175 Thousand CAD -91.52%
2019 2.06 Million CAD 0.0%
2018 - CAD 0.0%
2017 - CAD -100.0%
2016 1.39 Million CAD 0.0%
2015 - CAD 0.0%
2014 - CAD 0.0%
2013 - CAD 0.0%

Peer Total Debt Comparison of Hemostemix Inc.

Name Total Debt Total Debt Difference
Arch Biopartners Inc. 5.01 Million CAD 13.849%
Covalon Technologies Ltd. 1.56 Million CAD -176.582%
Universal Ibogaine Inc. 1.73 Million CAD -148.695%
Kane Biotech Inc. 8.27 Million CAD 47.783%
MedMira Inc. 9.27 Million CAD 53.388%
Marvel Biosciences Corp. 1 Million CAD -332.15%
NervGen Pharma Corp. 197.19 Thousand CAD -2091.543%
XORTX Therapeutics Inc. 15.17 Thousand CAD -28374.033%